Economic Burden of the Components of the Metabolic Syndrome

  • P. J. Marangos
  • L. J. Okamoto
  • J. J. Caro
Reference work entry


The components of the  metabolic syndrome have been extensively defined, studied, and debated. The prevalence has risen recently and affected patients use more health care resources, and face higher morbidity and mortality, resulting in an enormous economic burden. Some studies have shown health care costs to be as much as 20% higher than those accrued by patients without the risk factors. Patients with the metabolic syndrome have been shown to have greater drug expenditures, more frequent hospitalizations, and higher utilization of outpatient and physician services. When considered alone, the individual risk factor components account for a substantial economic burden to patients, health plans, and society as a whole. The diagnosis of the metabolic syndrome as a condition may encourage appropriate management and thus help prevent disease progression and reduce the considerable economic impact.


Metabolic Syndrome Health Care Cost Economic Burden Abdominal Obesity Medical Expenditure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


 Body Mass Index


Cardiovascular Disease


 Fasting Plasma Glucose


High Blood Pressure


High-Density Lipoprotein Cholesterol


International Statistical Classification of Diseases and Related Health Problems


International Diabetes Federation


 Impaired Glucose Tolerance


Low-Density Lipoprotein Cholesterol


Medical Expenditure Panel Survey


Third National Cholesterol Education Program Adult Treatment Panel


National Health and Nutrition Examination Survey


National Medical Expenditure Survey




World Health Organization


  1. AHA. (2005). Heart Disease and Stroke Statistics: 2005 Update. American Heart Association, Dallas, TX.Google Scholar
  2. Alberti KG, Zimmet P, Shaw J. (2005). Lancet. 366: (9491)1059–1062.PubMedCrossRefGoogle Scholar
  3. Alberti KG, Zimmet PZ. (1998). Diabet Med. 15(7): 539–553.PubMedCrossRefGoogle Scholar
  4. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. (2003). Diabetes. 52(5): 1210–1214.PubMedCrossRefGoogle Scholar
  5. American Heart Association. (2007). Metabolic Syndrome – Statistics. Retrieved on November 19, 2007, from
  6. Andreyeva T, Sturm R, Ringel JS. (2004). Obes Res. 12(12): 1936–1943.PubMedCrossRefGoogle Scholar
  7. Brixner D, Said Q, Kirkness C, Oberg B, Ben-Joseph R, Oderda G. (2007). Value Health. 10(S1): S29–S37.CrossRefGoogle Scholar
  8. Caro JJ, O’Brien JA, Hollenbeak CS, Spackman E, Ben-Joseph R, Okamoto L, Paramore LC. (2007). Value Health. 10(S1): S12–S20.CrossRefGoogle Scholar
  9. Castelli WP. (1999). Am J Obstet Gynecol. 180(6 Pt 2): S349–S356.PubMedCrossRefGoogle Scholar
  10. CDC. (2005). Preventing Heart Disease and Stroke: Addressing the Nation’s Leading Killers. Centers for Disease Control, Atlanta.Google Scholar
  11. Curtis LH, Hammill BG, Bethel MA, Anstrom KJ, Gottdiener JS, Schulman KA. (2007). Diabetes Care. 30(10): 2553–2558.PubMedCrossRefGoogle Scholar
  12. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. (2006). Lancet. 368(9548): 1651–1659.PubMedCrossRefGoogle Scholar
  13. Druss BG, Marcus SC, Olfson M, Tanielian T, Elinson L, Pincus HA. (2001). Health Aff (Millwood). 20(6): 233–241.CrossRefGoogle Scholar
  14. Eckel RH, Grundy SM, Zimmet PZ. (2005). Lancet. 365(9468): 1415–1428.PubMedCrossRefGoogle Scholar
  15. Encinosa WE, Bernard DM, Steiner CA, Chen CC. (2005). Health Aff (Millwood). 24(4): 1039–1046.CrossRefGoogle Scholar
  16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001a). JAMA. 285(19): 2486–2497.Google Scholar
  17. Fine M. (2007). Value Health. 10(Suppl 1): S2–S3.CrossRefGoogle Scholar
  18. Finkelstein E, Brown DS, Trogdon JG, Segal JE, Ben-Joseph R. (2007). Value Health. 10(S1): S45–S51.CrossRefGoogle Scholar
  19. Finkelstein E, Fiebelkorn C, Wang G. (2005). Am J Health Promot. 20(1): 45–51.PubMedGoogle Scholar
  20. Finkelstein EA, Fiebelkorn IC, Wang G. (2003). National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff (Millwood). (Suppl Web Exclusives): W3-219–W3-226.Google Scholar
  21. Fitch K, Pyenson B, Iwasaki K. (2007). Value Health. 10(S1): S21–S28.CrossRefGoogle Scholar
  22. Flegal KM. (2005). Physiol Behav. 86(5): 599–602.PubMedCrossRefGoogle Scholar
  23. Flegal KM, Carroll MD, Ogden CL, Johnson CL. (2002). JAMA. 288(14): 1723–1727.PubMedCrossRefGoogle Scholar
  24. Ford ES. (2005a). Diabetes Care. 28(11): 2745–2749.PubMedCrossRefGoogle Scholar
  25. Ford ES. (2005b). Diabetes Care. 28(7): 1769–1778.PubMedCrossRefGoogle Scholar
  26. Ford ES, Giles WH. (2003). Diabetes Care. 26(3): 575–581.PubMedCrossRefGoogle Scholar
  27. Ford ES, Giles WH, Dietz WH. (2002). JAMA. 287(3): 356–359.PubMedCrossRefGoogle Scholar
  28. Ford ES, Giles WH, Mokdad AH. (2004). Adults Diabetes Care. 27(10): 2444–2449.CrossRefGoogle Scholar
  29. French MT, Mundt MP, Fleming M, Zavala SK. (2005). J Intern Med. 258(1): 45–54.PubMedCrossRefGoogle Scholar
  30. Giannini E, Testa R. (2003). Arch Intern Med. 163(22): 2787–2788.PubMedCrossRefGoogle Scholar
  31. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. (2004). J Occup Environ Med. 46(4): 398–412.PubMedCrossRefGoogle Scholar
  32. Greenlund KJ, Zheng ZJ, Keenan NL, Giles WH, Casper ML, Mensah GA, Croft JB. (2004). Arch Intern Med. 164(2): 181–188.PubMedCrossRefGoogle Scholar
  33. Grundy SM, Brewer HB Jr., Cleeman JI, Smith SC Jr., Lenfant C. (2004a). Circulation. 109(3): 433–438.PubMedCrossRefGoogle Scholar
  34. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr Spertus JA, Costa F. (2005). Cardiol Rev. 13(6): 322–327.PubMedGoogle Scholar
  35. Grundy SM, Hansen B, Smith SC Jr., Cleeman JI, Kahn RA. (2004b). Circulation. 109(4): 551–556.PubMedCrossRefGoogle Scholar
  36. Haller H. (1977). Z Gesamte Inn Med. 32(8): 124–128.PubMedGoogle Scholar
  37. Han TS, Williams K, Sattar N, Hunt KJ, Lean ME, Haffner SM. (2002). Obes Res. 10(9): 923–931.PubMedCrossRefGoogle Scholar
  38. Hing E, Cherry D, Woodwell D. (2006). Adv Data. 374: 1–33.PubMedGoogle Scholar
  39. Hodgson TA, Cai L. (2001). Med Care. 39(6): 599–615.PubMedCrossRefGoogle Scholar
  40. Hoerger TJ, Ahmann AJ. (2008). J Manag Care Pharm. 14(1 Suppl C): S2–S14.PubMedGoogle Scholar
  41. Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, Zhang P, Engelgau MM. (2007). Diabetes Care. 30(11): 2874–2879.PubMedCrossRefGoogle Scholar
  42. Hogan P, Dall T, Nikolov P. (2003). Diabetes Care. 26(3): 917–932.PubMedCrossRefGoogle Scholar
  43. Hollenbeak CS, Spackman E, Ben-Joseph R, Okamoto L, Luce BR, Schwartz JS, Sullivan S. (2007). Value Health. 10(S1): S4–S11.CrossRefGoogle Scholar
  44. (2008). ICD-9-CM Database. from
  45. IMS Health Incorporated. (2006). Leading therapy classes by global pharmaceutical sales. Retrieved October 26, 2007, from,2777,6599_80528184_80530441,00.html.
  46. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. (2001). Diabetes Care. 24(4): 683–689.PubMedCrossRefGoogle Scholar
  47. Joslin E. (1921). JAMA. 76: 79–84.Google Scholar
  48. Kahn R, Buse J, Ferrannini E, Stern M. (2005). Diabetes Care. 28(9): 2289–2304.PubMedCrossRefGoogle Scholar
  49. Klein BE, Klein R, Lee KE. (2002). Diabetes Care. 25(10): 1790–1794.PubMedCrossRefGoogle Scholar
  50. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. (2002). Am J Epidemiol. 156(11): 1070–1077.PubMedCrossRefGoogle Scholar
  51. Laaksonen DE, Niskanen L, Lakka HM, Lakka TA, Uusitupa M. (2004). Ann Med. 36(5): 332–346.PubMedCrossRefGoogle Scholar
  52. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. (2002). JAMA. 288(21): 2709–2716.PubMedCrossRefGoogle Scholar
  53. Levitan EB, Song Y, Ford ES, Liu S. (2004). Arch Intern Med. 164(19): 2147–2155.PubMedCrossRefGoogle Scholar
  54. Lindsay RS, Howard BV. (2004). 4(1): 63–68.Google Scholar
  55. Lipsy RJ. (2003). Am J Manag Care. 9(2): S39–S58.PubMedGoogle Scholar
  56. Medco. (2007). Humanomics: understand the cost of cutting edge healthcare. Drug Trend Report. cat=5.
  57. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D’Agostino RB, Wolf PA. (2006). Arch Intern Med. 166(1): 106–111.PubMedCrossRefGoogle Scholar
  58. Nichols GA, Brown JB. (2002). Diabetes Care. 25(3): 482–486.PubMedCrossRefGoogle Scholar
  59. Nichols GA, Brown JB. (2005). Diabetes Care. 28(9): 2223–2229.PubMedCrossRefGoogle Scholar
  60. O’Donnell CJ, Ridker PM, Glynn RJ, Berger K, Ajani U, Manson JE, Hennekens CH. (1997). Circulation. 95(5): 1132–1137.PubMedGoogle Scholar
  61. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. (2006). JAMA. 295(13): 1549–1555.PubMedCrossRefGoogle Scholar
  62. Raebel MA, Malone DC, Conner DA, Xu S, Porter JA, Lanty FA. (2004). Arch Intern Med. 164(19): 2135–2140.PubMedCrossRefGoogle Scholar
  63. Rubins HB, Robins SJ, Collins D. (1996). Am J Cardiol. 78(5): 572–575.PubMedCrossRefGoogle Scholar
  64. Scranton RE, Bozeman SR, Burton TM, Hoaglin DC, Sirko S, Hollenbeak CS, Wilson PW. (2007). Value Health. 10(S1): S37–S44.CrossRefGoogle Scholar
  65. Singer P. (1977). Diagnosis of primary hyperlipoproteinemias. Z Gesamte Inn Med. 32(9): 129–133.PubMedGoogle Scholar
  66. Smith DG. (2007). Am J Manag Care. Suppl. 3: S68–S71.Google Scholar
  67. Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ. (2007). Curr Med Res Opin. 23(3): 553–563.PubMedCrossRefGoogle Scholar
  68. Stephens JM, Botteman MF, Hay JW. (2006). J Manag Care Pharm. 12(2): 130–142.PubMedGoogle Scholar
  69. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. (2006). BMJ. 332(7546): 878–882.PubMedCrossRefGoogle Scholar
  70. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. (2004). Circulation. 110(23): 3512–3517.PubMedCrossRefGoogle Scholar
  71. Thompson D, Brown JB, Nichols GA, Elmer PJ, Oster G. (2001). Obes Res. 9(3): 210–218.PubMedCrossRefGoogle Scholar
  72. Thorpe KE, Florence CS, Howard DH, Joski P. (2005). Health Aff (Millwood). Suppl Web Exclusives: W5-317–W5-325.Google Scholar
  73. Thorpe KE, Howard DH. (2006). Health Aff (Millwood). 25(5): w378–w388.CrossRefGoogle Scholar
  74. Todaro JF, Con A, Niaura R, Spiro A, 3rd, Ward KD, Roytberg A. (2005). Am J Cardiol. 96(2): 221–226.PubMedCrossRefGoogle Scholar
  75. Vague J, Vague P, Tramoni M, Vialettes B. (1983). Tohoku J Exp Med. 141: 147–159.PubMedCrossRefGoogle Scholar
  76. Vasan RS, Pencina MJ, Cobain M, Freiberg MS, D’Agostino RB. (2005). Ann Intern Med. 143(7): 473–480.PubMedGoogle Scholar
  77. Vijan S, Hayward RA. (2003). Ann Intern Med. 138(7): 593–602.PubMedGoogle Scholar
  78. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. (2005). Circulation. 112(20): 3066–3072.PubMedCrossRefGoogle Scholar
  79. Wolf AM, Colditz GA. (1998). Obes Res. 6(2): 97–106.PubMedGoogle Scholar
  80. Xu KT, Moloney M, Phillips S. (2003). Am J Manag Care. 9(8): 529–536.PubMedGoogle Scholar
  81. Zimmet P, Alberti KG, Shaw J. (2001). Nature. 414(6865): 782–787.PubMedCrossRefGoogle Scholar
  82. (2001b). The Hidden Competitive Edge. Employers Health Coalition: 1–12.
  83. (Medco Health Solutions). News release: Proprietary research reveals: metabolic syndrom – the costliest condition you’ve never heard of afflicts nearly one in four Americans. Retrieved February 21, 2008. print&ID=706992&highlight

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • P. J. Marangos
  • L. J. Okamoto
  • J. J. Caro

There are no affiliations available

Personalised recommendations